In a phase 2 trial of 70 adults with AChR antibody-positive generalised myasthenia gravis, oral vemircopan (180 mg or 120 mg) did not improve the MG-ADL responder rate vs placebo (57% and 57% vs 64%) and the trial was stopped. One participant died of hepatic failure.
RCTn = 70
Saccà et al. Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical Trial